Loading...
J.M. Smucker Co (SJM) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown positive Q3 financial performance and has received some upward revisions in price targets, the overall sentiment is mixed. Technical indicators suggest a bullish trend, but options data and news sentiment indicate caution. The lack of strong proprietary trading signals and the absence of significant trading trends from hedge funds or insiders further support a hold recommendation.
The technical indicators show a bullish trend with MACD positively expanding, RSI at a neutral level, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The pre-market price of $116 is near the first resistance level (R1: 116.941), indicating limited immediate upside potential.

Strong Q3 financial results with a 7% YoY increase in revenue and positive engagement with Elliott Management.
Analysts have raised price targets, with some firms upgrading the stock to Buy.
The stock recently climbed 10% following strong earnings and operational improvement initiatives.
Gross margin dropped significantly by -11.95% YoY, indicating cost pressures.
Mixed analyst sentiment, with some firms expressing concerns about competitive risks and muted pricing in the consumer staples sector.
Broader market sentiment is negative for consumer staples, with recommendations to shift investments to healthcare.
In Q3 2026, J.M. Smucker reported a 7.02% YoY increase in revenue to $2.34 billion and a 9.35% YoY increase in net income to -$724.2 million. EPS improved by 9.16% YoY to -$6.79. However, gross margin dropped to 33.24%, down -11.95% YoY, reflecting cost pressures.
Recent analyst ratings are mixed. While firms like Wells Fargo and BofA upgraded the stock and raised price targets (e.g., $135 and $130), others like Morgan Stanley downgraded it due to competitive risks and limited margin recovery potential. The consensus reflects cautious optimism with a focus on operational improvements.